Evidence map›Paper›PMID 10851052›Full record

ReviewOncogene2000

IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled.

E P Reddy, A Korapati, P Chaturvedi, S Rane

Abstract readReview
PubMed Publisher
In one paragraph

Review in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 226 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. An Update on Immune Based Therapies in Acute Myeloid Leukemia: 2021 and Beyond!Advances in experimental medicine and biology · 2021
    Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

E P ReddyFels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, 3307 N Broad Street, Philadelphia, Pennsylvania, PA 19140, USA.
A Korapati
P Chaturvedi
S Rane
Temple University · US

Funding

Regulation of DNA Double-Strand Break RepairR01CA098239 · NCI · MEDICAL COLLEGE OF GEORGIA (MCG) · PI DYNAN, WILLIAM S. · 2004 to 2013
$2.1M
AATYK--A NOVEL APOPTOSIS ASSOCIATED TYROSINE KINASER01ES009225 · NIEHS · TEMPLE UNIVERSITY · PI REDDY, E PREMKUMAR · 1998 to 2002
$699k
NCI NIH HHS CA98239NIEHS NIH HHS ES09225
6 · The paper itself

Abstract

Hematopoiesis is the cumulative result of intricately regulated signal transduction cascades that are mediated by cytokines and their cognate receptors. Proper culmination of these diverse signaling pathways forms the basis for an orderly generation of different cell types and aberrations in these pathways is an underlying cause for diseases such as cancer. Over the past several years, downstream events initiated upon cytokine/growth factor stimulation have been a major focus of biomedical research. As a result, several key concepts have emerged allowing a better understanding of the complex signaling processes. A group of novel transcription factors, termed signal transducers and activators of transcription (STATs) appear to orchestrate the downstream events propagated by cytokine/growth factor interactions with their cognate receptors. Until recently, the JAK proteins were considered to be the tyrosine kinases, which dictated the levels of phosphorylation and activation of STAT proteins, forming the basis of the JAK-STAT model. However, over the past few years, increasing evidence has accumulated which indicates that at least some of the STAT protein activation may be mediated by members of the Src gene family following cytokine/growth factor stimulation. Studies have demonstrated that the Src-family of tyrosine kinases can phosphorylate and activate certain STAT proteins, in lieu of JAK kinases. In such a scenario, JAK kinases may be more crucial to phosphorylation of the cytokine/growth factor receptors and in the process create docking sites on the receptors for binding of SH2-containing proteins such as STATs, Src-kinases and other signaling intermediates. Tyrosine phosphorylation and activation of STAT proteins can be achieved either by JAKs or Src-kinases depending on the nature of STAT that is being activated. This forms the basis for the JAK-Src-STAT model proposed in this review. The concerted action of JAK kinases, members of the Src-kinase family and STAT proteins, leads to cell proliferation and cell survival, the end-point of the cytokine/growth factor stimulus. Oncogene (2000).

Indexed as

Signal TransductionAnimalsApoptosisCytokinesDNA-Binding ProteinsHumansInterleukin-3Janus Kinase 1Phosphatidylinositol 3-KinasesProtein-Tyrosine KinasesReceptors, Interleukin-3src-Family KinasesSTAT1 Transcription FactorTrans-ActivatorsTranscriptional ActivationCytokinesDNA-Binding ProteinsInterleukin-3JAK1 protein, humanJanus Kinase 1Phosphatidylinositol 3-KinasesProtein-Tyrosine KinasesReceptors, Interleukin-3src-Family KinasesSTAT1 protein, humanSTAT1 Transcription FactorTrans-Activators

Identifiers

PMID10851052
OpenAlexW1990896527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.